Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
NCT06316297 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a Core Study followed by an optional Long-Term Extension (LTE). The Core Study will consist of a Sentinel Cohort A paired with a Main Cohort, evaluating the safety and efficacy of the 2-administration regimen and a Sentinel Cohort B, evaluating the safety of the 3- administration regimen. The Sentinel Cohorts will assess the safety of the dose levels and regimens in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long-term effects of the vaccine.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Acne mRNA vaccine
Study Locations (20)
California
- Private Practice - Dr. Francisco Badar- Site Number : 8400067 — Cerritos
- Encino Research Center- Site Number : 8400033 — Encino
- Paradigm Clinical Research Centers- Site Number : 8400064 — La Mesa
- Sunwise Clinical Research- Site Number : 8400108 — Lafayette
- Chemidox Clinical Trials- Site Number : 8400075 — Lancaster
- Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400058 — Los Angeles
- LA Universal Research Center- Site Number : 8400059 — Los Angeles
- Alliance Clinical - West Hills- Site Number : 8400131 — Los Angeles
- Carbon Health - North Hollywood - NoHo West- Site Number : 8400076 — North Hollywood
- Northridge Clinical Trials - Northridge- Site Number : 8400053 — Northridge
- Profound Research - Dermatologist Medical Group of North County- Site Number : 8400099 — Oceanside
- Cura Clinical Research - Oxnard- Site Number : 8400062 — Oxnard
- Amicis Research Center, LLC- Site Number : 8400110 — Palmdale
- Empire Clinical Research - Pomona- Site Number : 8400055 — Pomona
- Peninsula Research Associates- Site Number : 8400102 — Rolling Hills Estates
- Artemis Institute for Clinical Research, LLC- Site Number : 8400103 — San Diego
- California Research Foundation- Site Number : 8400095 — San Diego
- NorthBay Clinical Research- Site Number : 8400066 — Santa Rosa
Arizona
- Center for Dermatology and Plastic Surgery- Site Number : 8400111 — Scottsdale
Florida
- Encore Medical Research of Boynton Beach- Site Number : 8400116 — Boynton Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2024-04-05 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06316297
The ClinicalTrials.gov registry entry for NCT06316297 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 43 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06316297 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06316297 about?
NCT06316297 is a clinical study titled "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne". The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a Core Study followed ...
What is the current status of trial NCT06316297?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2024-04-05. Estimated completion is 2028-08-31.
What conditions does trial NCT06316297 study?
This clinical trial studies the following conditions: Acne. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06316297?
The interventions under investigation include: Placebo (OTHER), Acne mRNA vaccine (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06316297?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 43 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06316297 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.